Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | FDPS | P14324 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31039477 | 1.00 | RAB9A (0.53) | RAB9ANPC1KDM4EL3MBTL1MAPT | |
| SCHEMBL21579239 | 0.81 | RAB9A (0.47) | RAB9ANPC1KDM4EL3MBTL1MAPT | |
| SCHEMBL19867133 | 0.78 | TLR8 (0.47) | RAB9ANPC1KDM4EL3MBTL1MAPT | |
| SCHEMBL18995633 | 0.78 | NPC1 (0.45) | RAB9ANPC1KDM4EL3MBTL1MAPT | |
| SCHEMBL15368480 | 0.78 | NPC1 (0.61) | RAB9ANPC1KDM4EL3MBTL1MAPT | |
| SCHEMBL28324936 | 0.78 | RAB9A (0.40) | RAB9ANPC1KDM4EL3MBTL1MAPT | |
| SCHEMBL16828900 | 0.78 | RAB9A (0.43) | RAB9ANPC1KDM4EL3MBTL1MAPT | |
| SCHEMBL292777 | 0.76 | — | — | |
| SCHEMBL30671581 | 0.76 | — | — | |
| SCHEMBL14184980 | 0.75 | GAA (0.46) | RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737458-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| CN-110891951-B | Compounds of formula (I) | 谢菲尔德大学 | 2024-08-20 | — | — | CN | disclosed |
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-02-02 | — | — | US | disclosed |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11400081-B2 | Compounds | THE UNIVERSITY OF SHEFFIELD (GB) | 2022-08-02 | — | — | US | disclosed |
| CN-114007695-A | As AM2Heterocyclic spiro-compounds as receptor inhibitors | 谢菲尔德大学 | 2022-02-01 | — | — | CN | disclosed |
| US-20220023281-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2022-01-27 | — | — | US | disclosed |
| WO-2012064911-A1 | PIPERIDINONE CARBOXAMIDE INDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-17 | — | — | US | disclosed |
| WO-2011005731-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONIST | MERCK SHARP & DOHME CORP. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-7846931-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-20080125399-A1 | 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-05-29 | — | — | US | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| CN-1047774-C | Prepn of azadiphenyl cycloheptyl ketenes | HUALIAN PHARMACEUTICAL CO SHAN (CN) | 1999-12-29 | — | — | CN | disclosed |
| CN-1151987-A | Prepn of azadiphenyl cycloheptyl ketenes | SHANGHAI HUALIAN PHARMACEUTICA (CN) | 1997-06-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | RAB9A 758/4885NPC1 1284/4885KDM4E 4173/4885 |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | RAB9A 4200/4885NPC1 3053/4885KDM4E 2206/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | RAB9A 741/4885NPC1 1044/4885KDM4E 3893/4885 |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | RAB9A 758/4885NPC1 1284/4885KDM4E 4173/4885 |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, NR3C2 | RAB9A 1581/4885NPC1 1499/4885KDM4E 4724/4885 |
| US-20080125399-A1 | 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators | AR, CYP17A1, SHBG | RAB9A 4368/4885NPC1 3145/4885KDM4E 1067/4885 |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | RAB9A 4200/4885NPC1 3053/4885KDM4E 2206/4885 |
| US-11400081-B2 | Compounds | MRGPRX2, MC2R, ADM2 | RAB9A 1428/4885NPC1 805/4885KDM4E 4843/4885 |
| US-20220023281-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, AGTR1 | RAB9A 2987/4885NPC1 1561/4885KDM4E 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.